<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00076232</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 039</org_study_id>
    <secondary_id>1R01AI052054</secondary_id>
    <secondary_id>5U01AI047981-05</secondary_id>
    <secondary_id>DAIDS-ES ID 10066</secondary_id>
    <nct_id>NCT00076232</nct_id>
    <nct_alias>NCT00068965</nct_alias>
  </id_info>
  <brief_title>A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence
      of genital sores is a significant risk factor for becoming infected with HIV. This study will
      test the effectiveness of twice-daily dosing of acyclovir, a commonly prescribed anti-herpes
      drug, in preventing HIV infection in HSV-2 infected women who sleep with men (WSM) and men
      who sleep with men (MSM).

      Study hypothesis: Given that genital herpes is a significant risk factor to HIV acquisition,
      twice-daily HSV-2 suppressive therapy - 400 mg of acyclovir - will prevent HIV infection
      among high risk, HSV-2 seropositive WSM and MSM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many studies have shown that prior HSV-2 infection is associated with an increased risk for
      HIV infection. Acyclovir is the most widely studied and clinically utilized antiviral for the
      suppression of HSV-2 infection. This study will evaluate the efficacy of twice-daily dosing
      of acyclovir in preventing HIV infection in both WSM and MSM with genital herpes. For this
      study, WSM will be enrolled in Lusaka, Zambia; Harare, Zimbabwe; and Johannesburg, South
      Africa; MSM will be enrolled in Lima and Pucallpa, Peru; Seattle, Washington, USA; New York
      City, New York, USA; and San Francisco, California, USA.

      Participants will be enrolled for 12 months in this study and will be randomly assigned to
      one of two study arms. The first arm will receive 400 mg acyclovir twice daily; the second
      arm will receive placebo. Follow-up visits will occur monthly. Participants will be tested
      for STDs, including HIV and syphilis, at each visit and treated as necessary; participants
      will also be given adherence and condom counseling, risk behavior and sexual history
      questionnaires, and genital symptoms questionnaires at all study visits. Medical history will
      be assessed and participants will undergo blood work at Months 3, 6, 9, and 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serologically confirmed HIV infection</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence and frequency of genital ulcers</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of doses missed by study participants assigned to twice-daily acyclovir and twice-daily placebo</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3682</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV Seronegativity</condition>
  <condition>Herpes Genitalis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive acyclovir for the duration of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive acyclovir placebo for the duration of the trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir</intervention_name>
    <description>400 mg tablet taken orally twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir placebo</intervention_name>
    <description>Oral tablet taken twice daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria For All Participants:

          -  HIV-uninfected

          -  HSV-2 infected

          -  Plans to stay in the area for the duration of study participation

          -  Willing and able to provide consent, undergo clinical evaluations, take study drugs,
             adhere to follow-up schedule, and provide adequate locator information

        Inclusion Criteria for MSM:

          -  At least 1 episode of anal intercourse with another man within 6 months of study entry

        Inclusion Criteria for WSM:

          -  At least 1 episode of unprotected vaginal sex within 6 months of study entry

        Exclusion Criteria For All Participants:

          -  Current enrollment in another HIV vaccine or prevention trial

          -  History of adverse reaction to acyclovir

          -  Current or planned use of famiciclovir, valacyclovir, or acyclovir for genital HSV.
             Use of short-course antiviral therapy for herpes zoster after enrollment is allowed.

          -  Known plans for travel away from study site for more than 2 months

        Exclusion Criteria for MSM:

          -  In a mutually monogamous relationship with an HIV uninfected partner throughout the
             past 2 years

          -  Reported sex at birth as female

        Exclusion Criteria for WSM:

          -  Pregnancy at screening or enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Connie Celum, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Wald, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Department of Public Health, AIDS Office, Research Section</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Blood Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bruisten SM. Genital ulcers in women. Curr Womens Health Rep. 2003 Aug;3(4):288-98. Review.</citation>
    <PMID>12844451</PMID>
  </reference>
  <reference>
    <citation>Mbopi-Keou FX, Robinson NJ, Mayaud P, Belec L, Brown DW. Herpes simplex virus type 2 and heterosexual spread of human immunodeficiency virus infection in developing countries: hypotheses and research priorities. Clin Microbiol Infect. 2003 Mar;9(3):161-71. Review.</citation>
    <PMID>12667248</PMID>
  </reference>
  <reference>
    <citation>Schacker T. The role of HSV in the transmission and progression of HIV. Herpes. 2001 Jul;8(2):46-9. Review.</citation>
    <PMID>11867018</PMID>
  </reference>
  <reference>
    <citation>Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 2002 Jan 1;185(1):45-52. Epub 2001 Dec 14.</citation>
    <PMID>11756980</PMID>
  </reference>
  <results_reference>
    <citation>Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J, Buchbinder S, Koblin B, Zwerski S, Rose S, Wang J, Corey L; HPTN 039 Protocol Team. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Jun 21;371(9630):2109-19. doi: 10.1016/S0140-6736(08)60920-4.</citation>
    <PMID>18572080</PMID>
  </results_reference>
  <results_reference>
    <citation>Reid SE, Dai JY, Wang J, Sichalwe BN, Akpomiemie G, Cowan FM, Delany-Moretlwe S, Baeten JM, Hughes JP, Wald A, Celum C. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr. 2010 Apr;53(5):606-13. doi: 10.1097/QAI.0b013e3181bc4869.</citation>
    <PMID>19838129</PMID>
  </results_reference>
  <results_reference>
    <citation>Watson-Jones D, Wald A, Celum C, Lingappa J, Weiss HA, Changalucha J, Baisley K, Tanton C, Hayes RJ, Marshak JO, Gladden RG, Koelle DM. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials. J Clin Microbiol. 2010 Oct;48(10):3496-503. doi: 10.1128/JCM.01263-10. Epub 2010 Aug 11.</citation>
    <PMID>20702659</PMID>
  </results_reference>
  <results_reference>
    <citation>Curlin ME, Cassis-Ghavami F, Magaret AS, Spies GA, Duerr A, Celum CL, Sanchez JL, Margolick JB, Detels R, McElrath MJ, Corey L. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS. 2011 Jan 14;25(2):153-8. doi: 10.1097/QAD.0b013e328342115c.</citation>
    <PMID>21150554</PMID>
  </results_reference>
  <results_reference>
    <citation>Jacob ST, Baeten JM, Hughes JP, Peinado J, Wang J, Sanchez J, Reid SE, Delany-Moretlwe S, Cowan F, Fuchs JD, Koblin B, Griffith S, Wald A, Celum C. A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial. AIDS Behav. 2011 Jul;15(5):897-904. doi: 10.1007/s10461-010-9853-2.</citation>
    <PMID>21104007</PMID>
  </results_reference>
  <results_reference>
    <citation>SÃ¡nchez J, Sal Y Rosas VG, Hughes JP, Baeten JM, Fuchs J, Buchbinder SP, Koblin BA, Casapia M, Ortiz A, Celum C. Male circumcision and risk of HIV acquisition among MSM. AIDS. 2011 Feb 20;25(4):519-23. doi: 10.1097/QAD.0b013e328340fd81.</citation>
    <PMID>21099672</PMID>
  </results_reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2004</study_first_submitted>
  <study_first_submitted_qc>January 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2004</study_first_posted>
  <last_update_submitted>December 29, 2010</last_update_submitted>
  <last_update_submitted_qc>December 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rona Siskind</name_title>
    <organization>DAIDS</organization>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

